Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: A 3-year follow-up study

Wiener Klinische Wochenschrift

Volumn 126, Issue 3-4, 2014, Pages 133-137

  Markic, Josko ^a   Polic, Branka ^a   Stricevic, Luka ^a   Metlicic, Vitomir ^a   Kuzmanic Samija, Radenka ^a   Kovacevic, Tanja ^a   Ivkosic, Ivana Erceg ^b   Mestrovic, Julije ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b University Hospital Sveti Duh   (Croatia)

Author keywords

Cardiomyopathy; Glycogen storage disease type II; Immunomodulation; Infantile; Rituximab

Indexed keywords

DIPHENHYDRAMINE; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANTIBODY TITER; ARTICLE; CARDIOMYOPATHY; CASE REPORT; CONSERVATIVE TREATMENT; CROATIA; DRUG WITHDRAWAL; ECHOGRAPHY; ENZYME REPLACEMENT; FAILURE TO THRIVE; FEEDING DIFFICULTY; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE 2; HEPATOMEGALY; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; INFANT; INFUSION RELATED REACTION; IRRITABILITY; MACROGLOSSIA; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; OXYGEN DESATURATION; PALLOR; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; TRACHEOSTOMY; WHEEZING; DRUG COMBINATION; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CROATIA; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLOBULINS; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INJECTIONS, INTRAVENOUS; METHOTREXATE; TREATMENT OUTCOME;

EID: 84897024760     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0475-3     Document Type: Article

References (26)

1. Hirschhorn R, Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3389-420.
2. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008;372:1342-53.
3. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671-6.
4. Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7:713-6. (Pubitemid 29424063)
5. Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79:69-72. (Pubitemid 28402423)
6. Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013; 163(2):498-503.
7. Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11:210-9.
8. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99-109. (Pubitemid 46071892)
9. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3:132-8.
10. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010;362:1396-406.
11. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149:89-97. (Pubitemid 44081924)
12. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26-33.
13. Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13:729-36.
14. Lipinski SE, Lipinski MJ, Burnette A, Platts-Mills TA, Wilson WG. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab. 2009;98:319-21.
15. Markic J, Polic B, Kuzmanic-Samija R, et al. Immune modulation therapy in a CRIM-positive and IgG antibody-positive infant with Pompe disease treated with alglucosidase alfa: a case report. JIMD Rep. 2012;2:11-5.
16. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med. 2009;360:194-5.
17. Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab. 2012;106:301-9.
18. de Vries JM, van der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101:338-45.
19. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013;260:951-9.
20. Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol. 2008;152:138-46. (Pubitemid 351347554)
21. Banugaria S, Patel T, Prater S, et al. The use of non-depleting anti-CD4 monoclonal antibody for immune tolerance induction in Pompe disease. Mol Genet Metab. 2012;105:290.
22. Banugaria S, Prater S, Patel T, et al. Approach to management of cross-reactive immunologic material (CRIM)-negative infantile pompe patients treated with ERT: role of immune modulation in changing the natural history. Mol Genet Metab. 2013;108:23.
23. Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004;114:532-5.
24. Banugaria SG, Patel TT, Mackey J, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab. 2012;105:677-80.
25. Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2013;15:123-31.
26. Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet. 2012;160:69-79.